Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Erythropoietin levels and erythroid differentiation parameters in patients with lower-risk myelodysplastic syndromes.
Gurnari C, Latagliata R, Buccisano F, Piciocchi A, Fenu S, Mancini S, Fianchi L, Criscuolo M, Sarlo C, Romano A, Falconi G, Niscola P, Di Veroli A, Breccia M, Piccioni A, Aloe-Spiriti MA, Lo-Coco F, Voso MT; GROM-L (Gruppo Romano-Laziale MDS); GROM-L (Gruppo Romano-Laziale MDS). Gurnari C, et al. Among authors: sarlo c. Leuk Res. 2018 Aug;71:89-91. doi: 10.1016/j.leukres.2018.07.002. Epub 2018 Jul 10. Leuk Res. 2018. PMID: 30029156 No abstract available.
Pulmonary infections in patients with myelodysplastic syndromes receiving frontline azacytidine treatment.
Latagliata R, Niscola P, Fianchi L, Aloe Spiriti MA, Maurillo L, Carmosino I, Cesini L, Sarlo C, Piccioni A, Campagna A, De Luca ML, De Benedittis D, Mancini M, Breccia M, Criscuolo M, Buccisano F, Voso MT, Avvisati G, Tafuri A, De Fabritiis P, Foà R, Girmenia C. Latagliata R, et al. Among authors: sarlo c. Hematol Oncol. 2020 Apr;38(2):189-196. doi: 10.1002/hon.2710. Epub 2020 Jan 23. Hematol Oncol. 2020. PMID: 31891213
The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index.
Efficace F, Cottone F, Oswald LB, Cella D, Patriarca A, Niscola P, Breccia M, Platzbecker U, Palumbo GA, Caocci G, Stauder R, Ricco A, Petranovic D, Caers J, Luppi M, Fianchi L, Frairia C, Capodanno I, Follini E, Sarlo C, Fazi P, Vignetti M. Efficace F, et al. Among authors: sarlo c. Leukemia. 2020 Sep;34(9):2451-2459. doi: 10.1038/s41375-020-0746-8. Epub 2020 Feb 21. Leukemia. 2020. PMID: 32086447 Free PMC article.
SARS-CoV-2 in Myelodysplastic Syndromes: A Snapshot From Early Italian Experience.
Mossuto S, Attardi E, Alesiani F, Angelucci E, Balleari E, Bernardi M, Binotto G, Bosi C, Calvisi A, Capodanno I, Carbone A, Castelli A, Cerrano M, Ciancia R, Cilloni D, Clavio M, Clissa C, Crisà E, Crugnola M, Della Porta MG, Di Renzo N, Di Veroli A, Fattizzo R, Fava C, Fenu S, Ferrara IL, Fianchi L, Filì C, Finelli C, Giai V, Frattini F, Gaidano V, Guaragna G, Gumenyuk S, Latagliata R, Mancini S, Messa E, Molteni A, Musto P, Niscola P, Oliva E, Palumbo GA, Pelizzari A, Pilo F, Poloni A, Riva M, Rivellini F, Sarlo C, Sciumé M, Secchi R, Selleri C, Tafuri A, Santini V. Mossuto S, et al. Among authors: sarlo c. Hemasphere. 2020 Sep 23;4(5):e483. doi: 10.1097/HS9.0000000000000483. eCollection 2020 Oct. Hemasphere. 2020. PMID: 33062948 Free PMC article. No abstract available.
Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide.
Gurnari C, Piciocchi A, Soddu S, Bonanni F, Scalzulli E, Niscola P, Di Veroli A, Piccioni AL, Piedimonte M, Maiorana G, Salutari P, Cicconi L, Santopietro M, Gumenyuk S, Sarlo C, Fenu S, Tafuri A, Latagliata R, Fianchi L, Criscuolo M, Maciejewski JP, Maurillo L, Buccisano F, Breccia M, Voso MT. Gurnari C, et al. Among authors: sarlo c. Blood Cancer J. 2022 Sep 7;12(9):132. doi: 10.1038/s41408-022-00724-3. Blood Cancer J. 2022. PMID: 36071048 Free PMC article. No abstract available.
Health-related Quality of Life Profile of Newly Diagnosed Patients With Myelodysplastic Syndromes by Age, Sex, and Risk Group: A Real-world Study by the GIMEMA.
Efficace F, Al Essa W, Platzbecker U, Niscola P, Palumbo GA, Caocci G, Cottone F, Breccia M, Luppi M, Stauder R, Ricco A, Petranovic D, Baron F, Voso MT, Fianchi L, Frairia C, Capodanno I, Sarlo C, Fedele M, Lemoli RM, Invernizzi R, Vallisa D, Di Renzo N, Fozza C, Doro M, Giesinger JM, Vignetti M. Efficace F, et al. Among authors: sarlo c. Hemasphere. 2023 Aug 30;7(9):e944. doi: 10.1097/HS9.0000000000000944. eCollection 2023 Sep. Hemasphere. 2023. PMID: 37663671 Free PMC article.
Evaluation of the prognostic relevance of L-selectin and ICAM1 expression in myelodysplastic syndromes.
Buccisano F, Maurillo L, Tamburini A, Del Poeta G, Del Principe MI, Ammatuna E, Consalvo MI, Campagna S, Ottaviani L, Sarlo C, Renzi D, Faccia S, Fraboni D, Lo Coco F, Amadori S, Venditti A. Buccisano F, et al. Among authors: sarlo c. Eur J Haematol. 2008 Feb;80(2):107-14. doi: 10.1111/j.1600-0609.2007.00986.x. Epub 2007 Nov 17. Eur J Haematol. 2008. PMID: 18028430
Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy.
Sarlo C, Buccisano F, Maurillo L, Cefalo M, Di Caprio L, Cicconi L, Ditto C, Ottaviani L, Di Veroli A, Del Principe MI, Grasso MA, Nasso D, De Santis G, Amadori S, Venditti A. Sarlo C, et al. Leuk Res Treatment. 2013;2013:705714. doi: 10.1155/2013/705714. Epub 2013 Apr 28. Leuk Res Treatment. 2013. PMID: 23738080 Free PMC article.
33 results